BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen ZY, Wei W, Guo ZX, Peng LX, Shi M, Li SH, Xiao CZ, Zhong C, Qian CN, Guo RP. Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts. Br J Cancer 2014;110:733-40. [PMID: 24495874 DOI: 10.1038/bjc.2013.781] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Wu J, Ma XL, Tian L, Zhang CY, Wang BL, Hu YY, Gao XH, Zhou Y, Shen MN, Peng YF, Pan BS, Zhou J, Fan J, Yang XR, Guo W. Serum IgG4:IgG Ratio Predicts Recurrence of Patients with Hepatocellular Carcinoma after Curative Resection. J Cancer 2017;8:1338-46. [PMID: 28638447 DOI: 10.7150/jca.18030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
2 Yang MJ, Guo J, Ye YF, Chen SH, Peng LX, Lin CY, Hu T, Xie SH, Xie CB, Huang QH, Lu YQ, Liu Q, Qian CN, Cao SM. Decreased macrophage inflammatory protein (MIP)-1α and MIP-1β increase the risk of developing nasopharyngeal carcinoma. Cancer Commun (Lond) 2018;38:7. [PMID: 29764502 DOI: 10.1186/s40880-018-0279-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Kristono GA, Holley AS, Lakshman P, Brunton-O'Sullivan MM, Harding SA, Larsen PD. Association between inflammatory cytokines and long-term adverse outcomes in acute coronary syndromes: A systematic review. Heliyon 2020;6:e03704. [PMID: 32280800 DOI: 10.1016/j.heliyon.2020.e03704] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Abraham JA, Yeghiazaryan K, Golubnitschaja O. Selective internal radiation therapy in treatment of hepatocellular carcinoma: new concepts of personalization. Per Med 2016;13:347-60. [PMID: 29749819 DOI: 10.2217/pme-2016-0014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
5 Hochnadel I, Kossatz-Boehlert U, Jedicke N, Lenzen H, Manns MP, Yevsa T. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. Hum Vaccin Immunother. 2017;13:2931-2952. [PMID: 29112462 DOI: 10.1080/21645515.2017.1359362] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
6 Li B, Su H, Cao J, Zhang L. CXCL13 rather than IL-31 is a potential indicator in patients with hepatocellular carcinoma. Cytokine 2017;89:91-7. [PMID: 27663978 DOI: 10.1016/j.cyto.2016.08.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
7 Wang ST, Huang SW, Liu KT, Lee TY, Shieh JJ, Wu CY. Atorvastatin-induced senescence of hepatocellular carcinoma is mediated by downregulation of hTERT through the suppression of the IL-6/STAT3 pathway. Cell Death Discov 2020;6:17. [PMID: 32257389 DOI: 10.1038/s41420-020-0252-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Aryal B, Yamakuchi M, Shimizu T, Kadono J, Furoi A, Gejima K, Komokata T, Hashiguchi T, Imoto Y. Deciphering Platelet Kinetics in Diagnostic and Prognostic Evaluation of Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:9142672. [PMID: 30050894 DOI: 10.1155/2018/9142672] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
9 Lu LH, Wei-Wei, Kan A, Jie-Mei, Ling YH, Li SH, Guo RP. Novel Value of Preoperative Gamma-Glutamyltransferase Levels in the Prognosis of AFP-Negative Hepatocellular Carcinoma. Dis Markers 2020;2020:4269460. [PMID: 32695241 DOI: 10.1155/2020/4269460] [Reference Citation Analysis]
10 Li L, Chan SL, Mo F, Hui EP, Koh J, Chan AKC, Tang NLS, Lee KF, Lai PBS, Yu SCH, Yeo W. Correlations of health-related quality of life with serum inflammatory indicators IL-8 and mIBI in patients with hepatocellular carcinoma. Cancer Manag Res 2019;11:2719-27. [PMID: 31040713 DOI: 10.2147/CMAR.S178482] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
11 Li H, Zhang L. Liver regeneration microenvironment of hepatocellular carcinoma for prevention and therapy. Oncotarget 2017;8:1805-13. [PMID: 27655683 DOI: 10.18632/oncotarget.12101] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
12 Zhang Z, Chen Y, Jiang Y, Luo Y, Zhang H, Zhan Y. Prognostic and clinicopathological significance of CXCL1 in cancers: a systematic review and meta-analysis. Cancer Biol Ther 2019;20:1380-8. [PMID: 31387444 DOI: 10.1080/15384047.2019.1647056] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
13 Ye BG, Sun HC, Zhu XD, Chai ZT, Zhang YY, Ao JY, Cai H, Ma DN, Wang CH, Qin CD, Gao DM, Tang ZY. Reduced expression of CD109 in tumor-associated endothelial cells promotes tumor progression by paracrine interleukin-8 in hepatocellular carcinoma. Oncotarget 2016;7:29333-45. [PMID: 27121053 DOI: 10.18632/oncotarget.8787] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
14 Rai V, Abdo J, Alsuwaidan AN, Agrawal S, Sharma P, Agrawal DK. Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma. Mol Cell Biochem 2018;437:13-36. [DOI: 10.1007/s11010-017-3092-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]